120 related articles for article (PubMed ID: 37695535)
1. slan+ Monocytes Kill Cancer Cells Coated in Therapeutic Antibody by Trogoptosis.
Finotti G; Pietronigro E; Balanzin C; Lonardi S; Constantin G; Chao MP; Tecchio C; Vermi W; Cassatella MA
Cancer Immunol Res; 2023 Nov; 11(11):1538-1552. PubMed ID: 37695535
[TBL] [Abstract][Full Text] [Related]
2. slan
Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
[TBL] [Abstract][Full Text] [Related]
3. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
Decaup E; Rossi C; Gravelle P; Laurent C; Bordenave J; Tosolini M; Tourette A; Perrial E; Dumontet C; Poupot M; Klein C; Savina A; Fournié JJ; Bezombes C
Front Immunol; 2019; 10():1943. PubMed ID: 31475004
[TBL] [Abstract][Full Text] [Related]
4. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
[TBL] [Abstract][Full Text] [Related]
5. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
Beum PV; Lindorfer MA; Taylor RP
J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
[TBL] [Abstract][Full Text] [Related]
6. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
[TBL] [Abstract][Full Text] [Related]
7. Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20-opsonized B cells to neutrophil killing.
van Rees DJ; Brinkhaus M; Klein B; Verkuijlen P; Tool ATJ; Schornagel K; Treffers LW; van Houdt M; Kater AP; Vidarsson G; Gennery AR; Kuijpers TW; van Bruggen R; Matlung HL; van den Berg TK
Blood Adv; 2022 Apr; 6(7):2156-2166. PubMed ID: 34942000
[TBL] [Abstract][Full Text] [Related]
8. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
9. Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis.
Matlung HL; Babes L; Zhao XW; van Houdt M; Treffers LW; van Rees DJ; Franke K; Schornagel K; Verkuijlen P; Janssen H; Halonen P; Lieftink C; Beijersbergen RL; Leusen JHW; Boelens JJ; Kuhnle I; van der Werff Ten Bosch J; Seeger K; Rutella S; Pagliara D; Matozaki T; Suzuki E; Menke-van der Houven van Oordt CW; van Bruggen R; Roos D; van Lier RAW; Kuijpers TW; Kubes P; van den Berg TK
Cell Rep; 2018 Jun; 23(13):3946-3959.e6. PubMed ID: 29949776
[TBL] [Abstract][Full Text] [Related]
10. T cells, particularly activated CD4
Wang Z; Chimenti MS; Strouse C; Weiner GJ
Cancer Immunol Immunother; 2022 Feb; 71(2):237-249. PubMed ID: 34110453
[TBL] [Abstract][Full Text] [Related]
11. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
12. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
Cheney CM; Stephens DM; Mo X; Rafiq S; Butchar J; Flynn JM; Jones JA; Maddocks K; O'Reilly A; Ramachandran A; Tridandapani S; Muthusamy N; Byrd JC
MAbs; 2014; 6(3):749-55. PubMed ID: 24594909
[TBL] [Abstract][Full Text] [Related]
13. slan-defined subsets of CD16-positive monocytes: impact of granulomatous inflammation and M-CSF receptor mutation.
Hofer TP; Zawada AM; Frankenberger M; Skokann K; Satzl AA; Gesierich W; Schuberth M; Levin J; Danek A; Rotter B; Heine GH; Ziegler-Heitbrock L
Blood; 2015 Dec; 126(24):2601-10. PubMed ID: 26443621
[TBL] [Abstract][Full Text] [Related]
14. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity.
Rudnicka D; Oszmiana A; Finch DK; Strickland I; Schofield DJ; Lowe DC; Sleeman MA; Davis DM
Blood; 2013 Jun; 121(23):4694-702. PubMed ID: 23613524
[TBL] [Abstract][Full Text] [Related]
15. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells.
Sung AP; Tang JJ; Guglielmo MJ; Redelman D; Smith-Gagen J; Bateman L; Hudig D
J Immunol Methods; 2018 Jan; 452():63-72. PubMed ID: 29113954
[TBL] [Abstract][Full Text] [Related]
16. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
17. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present.
Kern DJ; James BR; Blackwell S; Gassner C; Klein C; Weiner GJ
Leuk Lymphoma; 2013 Nov; 54(11):2500-5. PubMed ID: 23452151
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
19. 6-Sulfo LacNAc (Slan) as a Marker for Non-classical Monocytes.
Hofer TP; van de Loosdrecht AA; Stahl-Hennig C; Cassatella MA; Ziegler-Heitbrock L
Front Immunol; 2019; 10():2052. PubMed ID: 31572354
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]